Lista de obras - Bolin Liu - Dominio Público Uruguay

"Sister" miRNAs in cancers.

artículo científico publicado en 2013

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.

artículo científico publicado en 2017

Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.

artículo científico publicado en 2001

Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.

artículo científico publicado en 2006

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

article

Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.

artículo científico publicado en 2005

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

artículo científico publicado en 2007

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

artículo científico publicado en 2010

Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.

artículo científico publicado en 2009

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

artículo científico publicado en 2001

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

artículo científico publicado en 2005

Glucose promotes breast cancer aggression and reduces metformin efficacy.

artículo científico publicado en 2013

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

artículo científico publicado en 2010

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

artículo científico publicado en 2011

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

artículo científico publicado en 2003

Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.

artículo científico publicado en 2015

Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.

artículo científico publicado en 2001

Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent.

artículo científico publicado en 2013

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

artículo científico publicado en 2016

Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

artículo científico publicado en 2013

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

artículo científico publicado en 2011

Role of erbB3 receptors in cancer therapeutic resistance.

artículo científico publicado en 2014

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.

artículo científico publicado en 2003

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

artículo científico publicado en 2017

Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells

artículo científico publicado en 2018

Targeting of erbB3 receptor to overcome resistance in cancer treatment

artículo científico publicado en 2014

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

artículo científico publicado en 2013

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

artículo científico publicado en 2015

The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway

artículo científico publicado en 2001

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

artículo científico publicado en 2011

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

scientific article published on January 2013

Lista de obras de Bolin Liu

"Sister" miRNAs in cancers.

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.

Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.

Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Glucose promotes breast cancer aggression and reduces metformin efficacy.

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.

Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.

Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent.

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

Role of erbB3 receptors in cancer therapeutic resistance.

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells

Targeting of erbB3 receptor to overcome resistance in cancer treatment

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.